Imagion Announces Positive Results from Phase 1 Study

Imagion Biosystems' Managing Director & CEO Dr. Isaac Bright details the positive results following the completion of the IBI10103 phase I clinical trial evaluating the safety and clinical feasibility of MagSense® HER2 Imaging Agent (MSH2IA) as an adjunct to MRI for the assessment of axillary lymph node metastasis in patients diagnosed with HER2+ primary breast cancer.

The trial met its endpoint of safety and tolerability, and showed that blinded radiologists may be able to distinguish suspicious lymph nodes that are infiltrated with metastatic HER2+ cancer from those involved in a healthy immune response or otherwise normally reactive.

Thirteen women definitively diagnosed with HER2+ breast cancer were enrolled and treated with the drug without any safety issues, toxicity or drug-related adverse events reported.